Ecovyst Inc. (ECVT) · Aug 5, 2026 · Company update

Revenue and adjusted EPS beat; guidance lift is largely acquisition-driven.

Revenue and adjusted EPS beat; guidance lift is largely acquisition-driven.

MetricQ2 2026 actualComparisonRead-through
Sales$250.0M$176.1M a year ago; published consensus $237.5MAbove expectation (Income Statement)
Adjusted diluted EPS$0.21$0.10 a year ago; published consensus $0.19Above expectation (Adjusted Net Income reconciliation)
Adjusted EBITDA$53.1M$41.9M a year ago+27%, but within management’s quarterly range (Adjusted EBITDA reconciliation)
Full-year Adjusted EBITDA outlook$195M–$207MPrevious $180M–$195MHeadline raise; acquisition contribution matters (2026 Outlook)
Adjusted EBITDA margin21.2%23.8% a year agoDown 2.6 percentage points despite higher sales (Adjusted EBITDA reconciliation)
Net leverage2.0x1.2x at December 31, 2025Higher after acquisition funding (Net Debt and Leverage table)

The quarter cleared the published bar, not just an easy year-ago comparison. Sales were about $12.5M above the published $237.5M expectation, while adjusted EPS of $0.21 exceeded the published $0.19 estimate. That makes the operating result a real, if modest, upside surprise; $53.1M of adjusted EBITDA was also 27% higher year over year.

The guidance increase is positive, but the headline overstates the organic upgrade. Full-year adjusted EBITDA moves to $195M–$207M from $180M–$195M. However, the legacy business range only raises its low end to $185M while retaining the $195M high end; the acquired Calabrian business is expected to supply $10M–$12M in second-half EBITDA. In other words, first-half execution improved the floor, but most of the consolidated increase reflects a transaction that had already closed rather than a broad reset of the pre-acquisition outlook.

Top-line growth was much stronger than profit growth. Sales rose 42%, but adjusted EBITDA rose 27% and adjusted EBITDA margin fell to 21.2% from 23.8%. About $55M of the sales increase came from sulfur-cost pass-through, which inflates revenue without producing equivalent margin; higher manufacturing, inflation, and transportation costs also weighed on conversion. The demand backdrop for regenerated acid remains favorable, but management still expects lower virgin-acid sales in the second half versus 2025 and flags softer industrial demand as a risk (Financial Highlights; Adjusted EBITDA reconciliation; 2026 Outlook).

Cash generation improved, but the balance sheet absorbed the acquisition. Six-month operating cash flow from continuing operations more than doubled to $55.2M, and adjusted free cash flow turned positive at $12.8M. Yet cash fell to $87.8M from $197.2M, net debt increased to $409.3M from $199.9M, and leverage rose to 2.0x following the $100M term-loan increase tied to Calabrian. The result is a stronger earnings and cash-flow profile, offset by less balance-sheet cushion and an integration burden that now matters to the full-year outcome (Cash Flow statement; Balance Sheet; Net Debt and Leverage table).

Original filing on SEC EDGAR

More Ecovyst Inc. news

Revenue and adjusted EPS beat; guidance lift is largely acquisition-driven. | ECVT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.